IN BRIEF: Roche rolls out new hepatitis D virus test

14. Jul 2026

(AWP Alliance News) - Roche Holding AG - Basel, Switzerland-based pharmaceutical company - Says it has launched a cobas hepatitis D virus test for clinicians. According to the company, it is "the first high-throughput, fully automated HDV assay on the market, addressing the urgent need for a consistent, widely accessible solution". The test is authorised for use in countries that recognise the EU's CE mark.

Matt Sause, chief executive Roche Diagnostics, comments: "This is an important advancement of our commitment to improving outcomes for people living with liver disease. With the cobas HDV test, we are providing clinicians with a reliable tool to aid in the identification of infected individuals and to monitor their response to treatment."

Current share price: CHF336.20

12-month change: up 23%

By Holly Munks, Alliance News reporter

Comments and questions to newsroom [at] alliancenews.com